Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial

Vaxart, Inc. announced positive topline results from a Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine. The trial...
Home/KnloSights/Clinical Trial Updates/Vaxart's Second-Generation Norovirus Vaccine Shows Significantly Increased Antibody Responses in Phase 1 Trial